

Curriculum Vitae



First Name: Alireza
Last Name: Khosravi Farsani
Date of Birth: 21.03.1967
Sex: Male
Marital Status: Married
Nationality: Iranian
Religion: Islam

Office:

Address: Isfahan University of Medical Sciences, Isfahan
Cardiovascular Research Institute, Hypertension Research Center & Alzahra
hospital P.O Box: 81465-1148, Isfahan, Iran.

Phone: +98 31 33377880, 33359797

Fax: +98 31 33373435

E-mail: alikh108@yahoo.com
Khosravi@crc.mui.ac.ir

Language Skills: Farsi, English

Education

- Isfahan University of medical science Iran, Doctor of medicine (M.D). 1985-1992
Theses Title: determination of prevalence of rheumatic fever in Iranian Population.
- Department of cardiology, faculty of medicine Isfahan Medical University, Isfahan, Iran.
Cardiologist (1995-1999)
Theses Title: Validity determination of ST depression during recovery period of exercise test
for diagnosis of CAD
- Department Of Interventional Cardiology. Faculty Of Medical Isfahan Medical University.
Isfahan, Iran Interventional Cardiologist. (2001-2003)
- different professional educational courses in different techniques in peripheral and
coronary intervention from Italy ,Belgium, Germany, Frances.

Employment

- Head of Interventional Cardiology Research Center. Isfahan. Iran
- Administrator of Hypertension research center, Isfahan, Iran
- Associated professor of interventional cardiology: Alzahra Hospital, Medical school, Isfahan University of Medical science, Isfahan Iran.
- Faculty member of Isfahan Cardiovascular research Center.

Specific Duties and Responsibilities:

- Research assistant of department of cardiovascular medicine. (???????)
- Head of the cardiology department of Alzahra hospital.
- Head of clinical research unit in Isfahan Cardiovascular Research Center. (2004-2006)
- Head of organizing and programming the intervention conference in chammran hospital (...May 2007).
- Deputy for science committee of national program (IHHP). (2000-2007).
- Head of educational programs for physicians in Isfahan Cardiovascular Research Center. (2004)
- Executive management for Isfahan Cardiovascular Research Center. (2004-2006)
- Holding Training Seminars on Secondary Prevention in Cardiovascular Diseases for physician with cooperation of WHO and Isfahan Cardiovascular Research Center

Work experience (training course):

- Head of Hypertension Research center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.(2011-2013)
- Coronary Intervention (11 years)
- peripheral vascular intervention (7 years)
- Participating in the training workshop on the method of international classification of diseases ICD 10-1999.
- Participating in the workshop of developed clinical trial in medical research 2003
- Participating in the fellow in vascular intervention Leuven belgium 2005 and 2009
- Participating in the workshop on Methods of Writing and Presenting Medical Articles, 1999.

Membership:

- Member of Research methods committee of Isfahan Cardiovascular Research Center.
- Member of Iranian Heart foundation, Iran, Isfahan Cardiovascular Research Center. And Iranian Heart friends.
- Member of Research council of Isfahan cardiovascular research center (2004-.....).
- Member of Research council of Isfahan University of Medical Sciences. (2013??)
- Member of public council of group PhD of Isfahan University of Medical Sciences.

- Member of editorial board Arya journal.
- Member of technical committee of Strategic Plan for Prevention and Control of Cardiovascular Diseases comprehensive map of the province's health.
- Member of هیئت ممتحنه ارتقاء-گواهینامه تخصصی رشته بیماریهای قلبی عروقی
- Member of publish committee of School of Medicine.
- Member of essential medical training programs In sections apprenticeship and heart.(2009)
- Member organizations multicenter research databases.(2006)
- Committee member financial evaluation of research projects Isfahan Cardiovascular Research Center.
- Member of editorial board and consultants team of Research in medical science Journal (from 2008)

Published Articles:

1. **Khosravi A**, Gharipour A, Gharipour M, Khosravi M, Andalib E, Shirani S, Mirmohammadsedghi M. Advanced method used for hypertension's risk factors stratification: support vector machines and gravitational search algorithm. *ARYA Atherosclerosis Journal*, 2015,11(6):349-356.
2. **Khosravi A**, Pourbehi M, Pourmoghaddas M, Ostovar A, Akhbari M, Ziaee-Bideh F, Golshahi J, Shirani S. Evaluating the impact of fractional flow reserve-guided percutaneous coronary intervention in intermediate coronary artery lesions on the mode of treatment and their outcomes: An Iranian experience. *ARYA Atherosclerosis Journal*, 2015; 11(4):220-227.
3. Etemadifar S, Bahrami M, Shahriari M, **Khosravi A**. Family Caregivers' Experiences of Caring for Patients With Heart Failure: A Descriptive, Exploratory Qualitative Study. *Journal of Nursing Research*, 2015;23(2):153-161.
4. Gharipour M, Sarrafzadegan N, Sadeghi M, **Khosravi A**, Hoseini M, Khosravi-Boroujeni H, Khaledifar A. The metabolic syndrome and associated lifestyle factors among the Iranian population. *Advanced Biomedical Research*, 2015; 4(1):1-6.
5. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, **Khosravi A**. Association between dietary salt intake and reservation of renal function in patients with mild hypertension. *ARYA Atherosclerosis Journal*, 2015; 11(Special Issue 1):1-5.
6. Gharipour M, Bahonar A, Sarrafzadegan N, **Khosravi A**, Khaledifar A. Are there any differences in education levels and changes of cardiovascular risk factors among urban and rural population: Isfahan Healthy Heart Program. *J Educ Health Promot*. 2015; 4:1-7.
7. Bahrami M, Etemadifar Sh, Shahriari M, **Khosravi A**. Informational needs and related problems of family caregivers of heart failure patients: A qualitative study. *Journal of Education and Health Promotion*, 2014; Nov (3):1-6.

8. Etemadifar S, Bahrami M, Shahriari M, Khosravi A. The effectiveness of a supportive educative group intervention on family caregiver burden of patients with heart failure. *Iranian Journal of Nursing and Midwifery Research*, 2014; 19(3):217-223.
9. **Khosravi A**, Gharipour M, Abdar M, Saadatnia M, Roghani F, Shirani S, Khaledifar A. Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers. *Advanced Biomedical Research*, 2014; 3(1):1-6.
10. **Khosravi A**, Pourheidar B, Roohafza H, Moezzi M, Mousavi M, Hajjannejad A, Bidram p, Gharipour M, Shirani S, Golshahi J, Boshtam M, Sarrafzadegan N. Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran. *ARYA Atherosclerosis Journal*, 2014; 10(6):311-318.
11. **Khosravi A**, Behjati M, Nilforoush P, Saieedi M, Balouchi A. A case of Marfan's syndrome with multi-level aortic dissections. *ARYA Atherosclerosis Journal*, 2014; 10(6):334-338.
12. Ashrafi F, Darakhshandeh A, Nematolahy P, **Khosravi A**. complete heart block in a patient with POEMS syndrome: A case report. *ARYA Atherosclerosis Journal*, 2014; 10(5):276-279.
13. Bahrami M, Etemadifar S, Shahriari M, **Khosravi A**. Caregiver burden among Iranian heart failure family caregivers: A descriptive, exploratory, qualitative study. *Iranian Journal of Nursing and Midwifery Research*, 2014; 19(1):56-63.
14. Hemmati R, Gharipour M, **Khosravi A**, Jozan M. A Cost-Benefit and Accurate Method for Assessing Microalbuminuria: Single versus Frequent Urine Analysis. Hindawi Publishing Corporation, *International Journal of Hypertension*, Volume 2013, Article ID 752903, 4 pages.
15. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, **Khosravi A**. Association between Salt Intake and Albuminuria in Normotensive and Hypertensive Individuals Hindawi Publishing Corporation, *International Journal of Hypertension*, Volume 2013, Article ID 523682, 4 pages.
16. Sadrnia S, Pourmoghaddas M, Hadizadeh M, Maghamimehr A, Esmaeeli M, Amirpour A, **Khosravi A**. Factors affecting outcome of primary percutaneous coronary intervention for acute myocardial infarction. *ARYA Atherosclerosis Journal*, 2013; 9(4):241-246.
17. **Khosravi A**, Noohi F, Andalib E, Sadeghiyan S, Peighambari M, Sarrafzadegan N and Working Group. Management of High Blood Pressure: The First Iranian High Blood Pressure Guideline (Summary), *Iranian Heart Journal* 2013; 13 (1):27-35.
18. Gharipour M, Ramezani M, Sadeghi M, **Khosravi A**, Masjedi M, Khosravi-Boroujeni H, Rafieian-kopaei M, Sarrafzadegan N. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. *Journal of Research in Medical Sciences*, 2013; 18:467-72.
19. Haghghatdoost F, Sarrafzadegan N, **Khosravi A**, Noori F, Boshtam M, Mohammadifard N, Abdollahi Z, Azadbakht L. Is the association between salt intake and blood pressure mediated by body mass index and central adiposity?. *Archives of Iranian medicine*. 2013; 16(3):167.

20. Najafian J, Toghianifar N, **Khosravi A**. Exertional abdominal pain as a symptom of secondary pulmonary hypertension in mitral stenosis. *Nigerian journal of clinical practice*. 2013;16(1):110.
21. **Khosravi A**, Jozan M, Gharipour M, Rowzati M, Khosravi E, Sarrafzadegan N. Effect of work place intervention in controlling hypertension. *Journal of Birjand University of Medical Sciences (supplementary: cardiovascular)*. 2013; 19 (6): 10-16.
22. **Khosravi A**, Hoseinabadi M, Pourmoghadas M, Shirani Sh, Paydari N, Sadeghi M, Kanani S, Jozan M, Khosravi E. Primary percutaneous coronary intervention in the Isfahan province, Iran; A situation analysis and needs assessment. *ARYA Atherosclerosis Journal*, 2013; 9 (1):38-44.
23. **Khosravi A**, Raoufi A, Pourmoghadas M, Paydari N, Gharipour M, Namdari M, Khaledifar A, Khosravi M, Bahonar A, Ostovan M, Hasanzadeh M, Sarrafzadegan N. Late clinical events of drug eluting versus bare metal stenting; OPCES' ancillary study. *Pak J Med Sci*, 2013; 29(1):258-263.
24. Gharipour M, Kelishadi R, **Khosravi A**, Shirani Sh, Masjedi M, Sarrafzadegan N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. *Arch Med Sci*, 2012; 8(6):1009-1017
25. Noohi F, Sarrafzadegan N, **Khosravi A**, Andalib E. The first Iranian recommendations on prevention, evaluation and management of high blood pressure. *ARYA Atherosclerosis Journal*, 2012; 8(3):97-118
26. **Khosravi A** Toghianifar N, Sarrafzadegan N, Gharipour M, Azadbakht L. Salt intake, obesity, and pre-hypertension among Iranian adults: A cross-sectional study. *Pak J Med Sci*, 2012; 28(2):297-302
27. **Khosravi A**, Rowzati M, Gharipour M, Gholamali Fesharaki M, Shirani S, Shahrokhi S, Jozan M, Khosravi E, Khosravi Z, Sarrafzadegan N. Hypertension control in industrial employees: findings from SHIMSCO study. *ARYA Atherosclerosis journal* 2012; 7(4):191-196.
28. Ansari R, **Khosravi A**, Bahonar A, Shirani S, Kelishadi R, Khosravi Z. Risk factors of atherosclerosis in male smokers, passive smokers, and hypertensive nonsmokers in central Iran. *ARYA Atherosclerosis Journal*. 2012; 8(2).
29. **Khosravi A**, Ansari R, Shirani Sh, Baghai A, Sarrafzadegan N. Causes of failure to control hypertension in people over 65 years of age. *ARYA Atherosclerosis Journal*, 2012, 7(5):42-46.
30. **Khosravi A**, Kelishadi R, Sarrafzadegan N, Boshtam M, Nouri F, Zarfeshani S, Esmailzadeh A. Impact of a community-based lifestyle intervention program on blood pressure and salt intake of normotensive adult population in a developing country. *J Res Med Sci* 2012; 17(3):235-241.
31. Shirani Sh, Samiee Nasab M, Samimi K, Forouzandeh M, **Khosravi A**. Comparison of sensitivity and specificity of cardiac size estimation through plain chest x-ray and two echocardiography. *ARYA Atherosclerosis Journal*, 2012, 7(5) (Special Issue):1-4.
32. Sabet B, Derakhshan R, Derakhshan F, Kelishadi R, **Khosravi A**. Association of body mass index, waist-to-hip ratio and waist circumference with cardiovascular risk

- factors: Isfahan Healthy Heart Program. ARYA Atherosclerosis Journal, 2012 (Special Issue); 7(5):47-50.
33. . Khosravi-Boroujeni H, Mohammadifard N, Sarrafzadegan NI, Sajjadi F, Maghroun M, **Khosravi A**, Alikhasi Hn, Rafieian M, Azadbakht L. Potato consumption and cardiovascular disease risk factors among Iranian population. Int J Fod Sci Nutr, 2012;63(8):913-20.
 34. **Khosravi A**, Akhavan Tabib A, Golshadi I, Dana Siadat Z, Bahonar A, Zarfeshani S, Alikhasi H, Rezaei Sh, Nouri F, Hashemi S.M. The Relationship between Weight and CVD Risk Factors in a Sample Population from central Iran (Based on IHHP). ARYA Atherosclerosis J, 2012, 8(2):82-89.
 35. Mohammadifard N, Fahimi S, **Khosravi A**, Pouraram H, Sajedinejad S, Pharoah P, Malekzadeh R, Sarrafzadegan N, Advocacy Strategies and Action Plans for Reducing Salt Intake in Iran. Archives of Iranian Medicine, 2012; 15(5): 320 – 324.
 36. Sarrafzadegan N, Gharipour M, Sadeghi M, **Khosravi A**, Tavassoli A. Metabolic syndrome in Iranian elderly. ARYA Atherosclerosis Journal, 2012; 7(4):157-61.
 37. Shemirani H , **Khosravi A**, Hemmati R, Gharipour M. Body Mass Index or Microalbuminuria, which one is more important for the prediction and prevention of diastolic dysfunction in Non-diabetic Hypertensive patients.Int J Prev Med.2012 Mar; 3(3):211-20.
 38. Shemirani H, Hemmati R, **Khosravi A**, Gharipour M, M Jozan. Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction.JRMS, 2012; 17(2); 133-137.
 39. Shirani Sh, Gharipour M, **Khosravi A**, Kelishadi R, Habibi H, Abdalvand A Sarrafzadegan N.Gender differences in the Prevalence of hypertension in a representative sample of Iranian population: the Isfahan Healthy Heart Program. Acta biomed, 2011:82(3):223-229.
 40. **Khosravi A**, Pourmoghaddas M,F Ziaie , Enteshari A, Khaledifar A, Bahonar A .Does lipoprotein (a)level have a predictive value in restenosis after coronary stenting.Int J Prev Med 2011Jul-Sep;2(3):158-163.
 41. Tavassoli A, Gharipour M, Toghianifar N, Sarrafzadegan N, **khosravi A**, Zolfaghari B, Zarfeshani S. The impact of obesity on hypertension and diabetes control following healthy Lifestyle Intervention Program in a developing country setting. JRMS 2011; 16(Special Issue): 368-376.
 42. **Khosravi A**, Pourmoghaddas M,Asadi K,Abdi A,Gholamrezaei A.Immediate results and six months outcomes after precutaneous coronary intervention in a referral heart center in Isfahan,Iran. ARYA Atherosclerosis Journal.2011;7(1).24.
 43. Sarrafzadegan N,Gharipour M,Ramezani M,Rabiei K,Zolfaghari B,Tavassoli A,Boshtam M,Zarfeshani S, Khosravi A,yousefi A. Metabolic syndrome and health-related quality of life in Iranian population.journal of research in medical science.2011;16(3):254-261.
 44. Gharipour M, Kelishadi R, Toghianifar N, Tavassoli A, **Khosravi A**, Sajadi F, Sarrafzadegan N. Socioeconomic Disparities And Smoking Habits in Metabolic

- Syndrome: Evidence from Isfahan Healthy Heart Program. Iran Red Crescent Med J 2011; 13(8):537-543.
45. Hemmati R, Gharipour M, Shemirani H, Khosravi A, Khosravi E. Urine Albumin to Creatinine Ratio and Echocardiographic Left Ventricular Structure and Function in Patients with Essential Hypertension. Am Heart Hosp J. 2011; 9(2); 90-4.
 46. Khosravi A, Pourmoghaddas M, Ostovan M, Kiani Mehr G, Gharipour M, Zakeri H, Soleimani B, Namdari M, Hassanzadeh M, Tavassoli A, Ghaffari S, Khaledifar A, Roghani F, Khosravi M, Sarami S, Kojouri J, Nouri F, Khosravi E, Jozan M, Sarrafzadegan N. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. JRMS 2011; 16(5): 640-650.
 47. Rajabizadeh G, Ramezani M, Roohafza H, Pourdamghan N, **Khosravi A**, Rabiei K, Sarrafzadegan N, Toghianifar N, Zarfeshani S. Association between cigarette smoking and socio-demographics, lifestyle and mental health factors in a sampled Iranian population. Southeast Asian J Trop Med Public Health 2011, 42(4):977-87.
 48. Akhlaghi A, Shirani S, Ziaie N, Pirhaji O, Yaran M, Shahverdi G, Sarrafzadegan N, **Khosravi A**, Khosravi E. Cytochrome p450 2c19 polymorphism in Iranian patient with coronary artery disease. ARYA Atherosclerosis journal 2011, 7(3):106-10.
 49. Sarrafzadegan N, Kelishadi R, Najafian A, **Khosravi A**, Bahonar A, Asgari S, Sadri G, Amani A, Eshrati B. Anthropometric indices in association with cardio metabolic risk factors: findings of the Isfahan healthy heart program. ARYA Atherosclerosis Journal 2010, 5(4): 152-162
 50. **Khosravi A**, Kiani mehr G, Kelishadi R, Shirani S, Gharipour M, Tavassoli A, Nouri F, Sarrafzadegan N. The impact of a 6-year comprehensive community trial on the awareness, treatment and control rates of hypertension in Iran: Experiences from the Isfahan healthy heart program. BMC cardiovascular disorders. 2010; 1-8.
 51. Sotodeh asl N, Neshat Dost H, Kalanteri M, Talebi H, **A Khosravi**. Comparison of the effectiveness of cognitive behavioral therapy and medication on the quality of life in the patients with essential hypertension. Semnan University of Medical Sciences 2010, 11(4):294-301.
 52. Sotodeh Asl N, Neshat Dost HT, Kalanteri M, Talebi H, **Khosravi A**. Comparison of the effectiveness of two methods of hope Therapy and Drug therapy on the quality of life in the patients with essential hypertension. Journal of clinical psychology. spring 2010; 2(1):27-34.
 53. Mohajer H, **Khosravi A**, Saadatnia M, Abdar M, Azarm T. Genetic Thromboembolic Risk Factors Associated with Deep Vein Thrombosis in a Iranian Population. Journal of Isfahan Medical School 2010, 28(114):795-800.
 54. **Khosravi A**, Akhavan Tabib A, Golshadi I, Dana Siadat Z, Bahonar A, Zarfeshani S, Alikhasi H, Rezaei Sh, Nouri F, Hashemi S.M. The Relationship between Weight and CVD Risk Factors in a Sample Population from central part of Iran (Based on IHHP). RJMS. 2010; 17 (72) :31-41
 55. Tavassoli A, Gharipour M, **Khosravi A**, Kelishadi R, Dana Siadat Z, Bahonar A, Sadri G, Sadeghi M, Rabiei K, Sajadi F, Zarfeshani S, Eshrati B, Shirani S, Sarrafzadegan N. Gender Differences in Obesogenic Behavior, Socioeconomic and Metabolic Factors

- in a Population-based Sample of Iranians: The IHHP Study, *J HEALTH POPUL NUTR* 2010 Dec;28(6):602-609.
56. **Khosravi A**, Ramezani M, Toghianifar N, Rabiei K, Jahandideh M, Yousofi A. Association between Hypertension and quality of life in a sample of Iranian adults. *ACTA Cardiol*, Aug 2010;65(4):425-430.
 57. Bahonar A, **Khosravi A**, Esmaeelian H, Babak A, Sarrafzadegan N, Rahmati M, Jamshidi A, Azad M, Daneshvar P. Methods of implement the operational phases of the health professionals education project-Isfahan healthy heart program (IHHP-HPEP), *ARYA Atherosclerosis Journal* 2009, 5(3): 103-107.
 58. Beigi A, Sadeghi A.M, **Khosravi A**, Karami M, Masoudpour H. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. *Journal of vascular access*. 2009;10(3).160.
 59. Kelishadi R, Sarrafzadegan N, Sadri G, Pashmi R, Mohammadifard N, Tavasoli A, Amani A, Rabiei K, **Khosravi A**, Bahonar A. Short-Term Results of a Community-Based Program on Promoting Healthy Lifestyle for Prevention and Control of Chronic Diseases in a Developing Country Setting: Isfahan Healthy Heart Program. *Asia Pac J Public Health*. Oct 2009.
 60. Sarrafzadegan N, Kelishadi R, Dana Siadat Z, Esmailzadeh A, Solhpour A, Shirani S, Naderi G, Asgari S, Sadri G, **Khosravi A**, Bahonar A. Obesity and cardio metabolic risk factors in a representative population of Iranian adolescents and adults in comparison to a Western population: the Isfahan Healthy Heart Programme. *Public Health Nutr*. 2009 Aug 6:1-10, 13(3), 314–323.
 61. Shirani S, Kelishadi R, Sarrafzadegan N, **Khosravi A**, Sadri G, Amani A, Heidari S, Ramezani M. Awareness, treatment and control of hypertension, dyslipidemia and diabetes mellitus in an Iranian population: the IHHP study. *East Mediterr Health J*, Nov-Dec 2009, 15(6);1455-63.
 62. **Khosravi A**, Avesta L, Ramezani M, Bahonar A, Heidari H, Tavassoli A, Sarrafzadegan N. Assessment of relation between microalbuminuria and ischemic electrocardiogram in Iranian general population. *ARYA Atherosclerosis journal*, spring 2009, 5(1):33-38.
 63. **Khosravi A**, Kelishadi R, Pourmoghaddas M, Shirani S, Asgari S, Khosravi M. Preprocedural C-reactive protein predictive value in angiographic in-stent restenosis after coronary stent placement in patients with stable angina. *ARCHIVES OF MEDICAL SCIENCE* 2009;5(2):166-171.
 64. Beigi A, **Khosravi A**, Sadeghi M, Safaei M. Cardiac performance in end stage renal disease diabetic patients with arteriovenous fistula. *ARYA Atherosclerosis journal*, 2008; 4(1):33-36.
 65. Sarrafzadegan N, Rabiei K, Kabir A, Sadeghi M, **Khosravi A**, Asgari S, Taghipour HR, Roohafza H. Gender differences in risk factors and outcomes after cardiac rehabilitation. *Acta Cardiol*. 2008 Dec; 63(6):763-70.
 66. Shahrokhi S, Kelishadi R, Sarrafzadegan N, **Khosravi A**, Roohafza H, Pooya A, Mollabashi R. Evaluation of the Quit and Win contest for smoking cessation in the Islamic Republic of Iran. *Iran. Eastern Mediterranean Health J*. Dec 2008, 14(6):1270-9.

67. **Khosravi A**, Movahedi B, Pourmoghaddas M, Ansari R. Paraxonas (PON) activity in Less than 40 years old non diabetic Patients with and without significant coronary artery disease. *ARYA Journal*, 2008,4(1):53-58.
68. Akhavan tabib. A, saeedi .M, Bahonar .A, **khosravi. A**, Dana Siadat .Z, Alikhasi H.the relationship between TG and high waist circumference with cardiovascular risk factor in female area of Iran. *medecal scientific journal*. 2008, 7(2).
69. Sarrafzadegan, N, Rabiei, K, Kabir A, **Khosravi A**, et al. Changes In Lipid Profile Of Patients Referred To A Cardiac Rehabilitation Program Source: *European Journal Of Cardiovascular Prevention & Rehabilitation* 2008; 15(4):467-472.
70. Sajjadi F, Mohammadifard N, **Khosravi A**, et al. Nutritional knowledge, attitude and practice of health professional about cardiovascular disease: results of Isfahan Healthy Heart Program. *Birjand University of Medical Sciences* 2008; 2 (15): 65-73.
71. Roghani F, **Khosravi A**, A Case report of acute dissection of LM during coronary angioplasty. *Shahrekord University of Medical Sciences* 2008; 10(1): 89-92.
72. Kelishadi, R Sharifi, **Khosravi A** et al. Relationship between C-reactive protein and atherosclerotic risk factors and oxidative stress markers among young person's 10-18 years old Source: *CLINICAL CHEMISTRY* 2007;53(3):456-464.
73. Kelishadi R, Mokhtari M, Tavasoli A, **Khosravi A**, Ahangar-Nazari I, Sabet B, Kazemi A, Amini A. Determinants of tobacco use among youths in Isfahan, Iran. *Int J Public Health*. 2007; 52(3):173-9.
74. Oveisgharan S, Sarrafzadegan N, Shirani S, **Khosravi A**, et al. Stroke in Isfahan, Iran: hospital admission and 28-day case fatality rate: *CEREBROVASCULAR DISEASES* 2007: 24(6):495-499.
75. **Khosravi A**, Abdi A, Sarrafzadegan N, Ansari R, Kianimehr G, Roghaei F, Siadat Z . The effect of low-dose niacin added to simvastatin on lipoprotein profile. *Arya Atherosclerosis* spring 2007:3(1):8-13.
76. Ansari. R, **Khosravi A**, Mokhtari M .Prevalence and cause of smoking in the medicine students *Journal of Semnan University of Medical Sciences*.2007 9(1):21-26.
77. Asgary S, Gharipour M, Naderi Gh, Sabet B, **Khosravi A**, Hashemi M. Measuring auto-anti body against modified LDL in cardiovascular patient. *Journal of cell and tissue research*.2007;7(1):899-903.
78. Shahrokhi S, Asgari S, **Khosravi A**, Naderi GH, Taheri M. The effect of nicotine gum on blood pressure and heart pate. *ARYA atherosclerosis J*, 2006; 1(4) 252-254.
79. Ashtari F, Shayegan-nejad V, Khosravi A, Saberi A, Niknazar M. The Influence of Chlamydia Pneumoniae Infection On Intima-Media-Thickness (Imt) In Common Carotid Artery. *ARYA Atherosclerosis Journal* 2006, 2(3): 130-133.
80. **Khosravi A**, Shirani SH, Shahrokhi SH, Mohammadifard N, Ansari R. Antihypertensive Drugs Used By Hypertensive Patients In The Provincial Cities Of Isfahan, Najafabad And Arak. *ARYA Atherosclerosis J* 2006; 1(4):275-81.
81. Shahrokhi Sh, **Khosravi A**, Asgary S, Javadi H.R. Kap study on smoking in Iranian medical doctor. *Qazvin Medical University Journal*. 2006; 9(4:47-52).
82. Kelishadi R, Sadri G, Tavasoli A, Kahbazi M, Roohafza H, Sadeghi M, **Khosravi A**, Sabet B, Amani A, Ansari R, Alikhasi H. Cumulative prevalence of risk factors for

- atherosclerotic cardiovascular diseases in Iranian adolescents: IHHP-HHPC. *J Pediatr (Rio J)*. 2005 Nov-Dec; 81(6):447-53.
83. Kelishad R, hashemipour M, Sadeghi M, Roohafza H.R, Tavasoli A.A, **Khosravi A**, Ansari R, Ansari Z, Bashardoust N. The impact of familial factors on obesity in Iranian children and adolescents. *J Ped Neonat*, 2005; 2(2): 16-23.
 84. **Khosravi A**, Pourmoghaddas M, Kelishadi R, Sabet B, Ansari R, Shirani SH, Sarrafzadegan N. Trends in blood pressure level, prevalence of hypertension and its care in Isfahan. *MJIRC* , 2005, 8(2):62-68.
 85. Kelishadi R, Derakhshan R, Sabet B, Sarrafzadegan N, Kahbazi M, Sadri G.H, Tavasoli A.A, Heidari A, **Khosravi A**, Amani A, Tolouei HR, Bahonar A, Rezaei Ashtiani AA, Moatari A. The metabolic syndrome in hypertensive and normotensive subjects: the Isfahan healthy heart program. *Annals Academy of Medicine*, 2005, 34(3):243-9
 86. **Khosravi A**, Ansari R, Shirani Sh. Causes of uncontrolled blood pressure in the over-65 population. *ARYA Journal* 2005, 1(2):101-105.
 87. **Khosravi A**, Ansari R, Shirani Sh. Blood pressure levels and trends of obesity in hypertensive patients versus health individuals: Isfahan 1991-2001. *ARYA Journal* 2005; 1(1):19-24
 88. Asgary S. Naderi GH, Gharipour M, Sabet B, **Khosravi A**, Invitro effect of nicotine and cotinine on the susceptibility of LDL oxidation and hemoglobin glycosylation. *The Journal of Qazvin univ of Med Sci*. 2005; 9(2): 20-25.
 89. Ansari R, **Khosravi A**, Bahonar A, Shirani SH, Kelishadi R. Prevalence of risk factors in mail smoker passive smokers and non smokers with hypertension in central Iran. 2005 Shahrekord medical science university. 2005 3(1): 23-34.
 90. **Khosravi A**, Ansari R, Shirani Sh, Baghai A .The Causes of failure to control hypertension in population aged over 65. *The Journal of Qazvin univ of Med Sci*. 2005, 35summer:8-14.
 91. **Khosravi A**, Mazarei A, Pourmoghaddas M, Ansari R, Shirani Sh. Comparison of the effect of Iranian atenolol tablets in the mild and moderate hypertension patients. *Shahrekord University of Medical Sciences* 2005; 3(1): 47-60.
 92. Shirani Sh, **Khosravi A**, Ansari R, Shahrokhi SH, Sajjadi F, Kelishadi R. One-intervention on the knowledge and practice about healthy nutrition in the central areas of Iran, IHHP Study. *Shahrekord University of Medical Sciences* 2005; 3(1): 84-97.
 93. **Khosravi A**, Pourmoghaddas M, Sarrafzadegan N, Ansari R, Kelishadi R, Shirani S, Sabet B. Trend of ten year of hypertension in adult in isfahan. *The journal of Shahrekord University of Medical Sciences*. 2004; 6(4):87-95.
 94. Pourmoghaddas M, **Khosravi A**, Kelishadi R, Sarrafzadegan N, Shirani S, Ansari R, Sabet B. Trends in Blood Pressure Level, Prevalence and Control of Hypertension in Isfahan, Iran. . *Iranian Heart Journal* 2004; 5(1,2):33-38.
 95. **Khosravi A**, Mohammadifard N, Shahrokhi Sh, Shirani Sh, Ansari R. Drugs used in hypertension patients in central part of Iran. *J Isf Med school*. 2004; 22(73 & 74).

96. Ansari R, **Khosravi A**, Sarrafzadegan N, Kelishadi R, Khosravi E. The relation of the blood pressure level and obesity in hypertensive and normotensive subjects in Isfahan 1991-2001. *Yasuj uni Med Sci* 2003; 8(30): 1-9.
97. Kelishadi R, Sabet B, **Khosravi A**. Anticardiolipin antibody adolescents and age of myocardial infarction in parents. *Med Sci Monit*, 2003;9(12):515-8
98. **Khosravi A**, Nasr A. Sabet B. Namazi M. Evaluation the knowledge and practice about cardiopulmonary resuscitation in hospital's Nurses. Interns and residents in Alzahra hospital. *J Isf Med school* (2003) 22(71).
99. Pourmoghaddas M, **Khosravi A**, Jamshidi R. 3 years experience in angioplasty, primary success, and effect of atherosclerotic risk factor on it. *J Isf Med school* 2001 19(63&64).
100. Pourmoghaddas M, **Khosravi A**, Kia B. prevalence coronary intervention Restenosis after PCI with and without stent implantation. *Shahrekord University of Medical Sciences*. 2001 3(2);22-30.
101. Kelishadi R, Rabiee K, **Khosravi A**, Famori F, Sadeghi M, Roohafza HR, Shirani SH. Evaluation of physical activity among adolescent in Isfahan. *The Journal of Shahrekord University of Medical Science* 2001; 2: 55-62.

Plans:

1. The amount of salt daily basis in 24-hour urinary excretion of sodium chloride in sodium chloride excretion in the urine of adults and accidental in children and adolescents and excretion of sodium chloride in random urine samples of adults in urban areas.
2. The threshold and the taste of salt and blood pressure sensitivity to salt in people with normal blood pressure measurement.
3. The effect of self-care programs and therapeutic localization solutions to improve the control of hypertension in Iran.
4. Develop strategies for prevention, treatment and control of hypertension native practices in Iran.
5. Design community sensitization and high-risk groups to reduce salt intake in Isfahan.
6. Acute Coronary Events a multinational Survey of Current Management Strategies.
7. Incidence of cardiovascular events Osvox drug consumption compared to Plavix after stent implantation in coronary arteries.
8. The amount of daily salt intake by 24-hour urinary excretion of sodium chloride in people over 18 years of Isfahan and Najaf Abad.
9. The effect of the treatment of cardiovascular risk factors on the risk of cardiovascular events in patients with hypertension, steel workers (first phase).
10. The effect of the treatment of cardiovascular risk factors on the risk of cardiovascular events in patients with hypertension, steel workers (second phase).

Supervised Thesis's:

1. Prevalence of short-term complications (MACE) in patients with acute myocardial infarction after Percutaneous Coronary Intervention Isfahan Chamran Hospital during six months.

2. Year clinical outcomes in patients with coronary artery disease in the years 1389-1387 in Isfahan Chamran Hospital Percutaneous Coronary Intervention had been in 1390.
3. Immediate results and six-month outcomes after percutaneous coronary intervention in a referral heart center in Isfahan, Iran.
4. Polymorphism analyzes the distribution of P450 2C19 * 2 (alleles responsible for resistance to Clopidogrel) in patients with coronary stents who are Persians.
5. Comparison of major cardiovascular events in percutaneous coronary intervention with drug-eluting stent MACE DES versus non-pharmacological stents in one-year follow-up study OPCES.
6. Evaluation of cardiac diastolic function in hypertensive patients with proteinuria, the first being that complication.
7. Deep venous thrombosis genetic risk factors set foot in Iran.
8. THE EFFECT OF LOW-DOSE NIACIN ADDED TO SIMVASTATIN ON LIPOPROTEIN PROFILE.
9. Paraxonase (Pon) Activity In Less Than 40 Years Old Nondiabetic Patients With And Without Significant Coronary Artery Disease.

Invited Speaker:

Scientific Lectures inviter speaker:

1. Definitions, Epidemiology of Hypertension. International Congress on Cardiac Emergencies. 19-21 February 2014. Bandar Abbas, Iran
2. Review on hypertension and salt intake in Iran. 2nd International Preventive Cardiology Congress. 16-18 October 2013, Shiraz-Iran.
3. The First International Congress on Prevention, Diagnosis & Management of Hypertension. 27 – 29 Sep. 2011 , Isfahan – Iran.
4. Developing Iranian guidelines for hypertension treatment and control the 13th International Symposium on Hypertension and Related Diseases November 3-6 2011, Beijing, China.
5. Salt reduction experience and strategies in Iran. The 13th International Symposium on Hypertension and Related Diseases November 3-6 2011, Beijing, China.
6. The role of community-based lifestyle intervention on salt intake and blood pressure in Iran. Munich, Germany 2012. (Poster).
7. Hypertension control in Industrial impact of shimsco Study in Iran. Munich, Germany 2012. (Poster).
8. 2nd Middle East Preventive Cardiology Congress. 16-18 October 2013, Shiraz, Iran.

Congresses

A. International

- 1- The First International Congress on Prevention, Diagnosis & Management of Hypertension. 27 – 29 Sep. 2011, Isfahan – Iran.
- 2- The 13th International Symposium on Hypertension and Related Diseases November 3-6 2011, Beijing, China.
- 3- Treatment choice in hypertension: evidence versus conventional opinion, Munich, Germany, Saturday, August 25, 2012.
- 4- 2nd Middle East Preventive Cardiology Congress. 16-18 October 2013, Shiraz, Iran.
- 5- International Congress on Cardiac Emergencies. 19-21 February 2014. Bandar Abbas, Iran
- 6- 1st International Congress Cardiac Rehabilitation from research to practice. 21-23 October 2014, Isfahan, Iran.

B. National

۱. ششمین کنگره سراسری تازه های قلب و عروق، مشهد، (روند ۱۰ ساله پرفشاری خون در افراد ۱۸ ساله شهر اصفهان/ همبستگی چاقی براساس شاخص توده بدنی، نسبت دور شکم به دور لگن و اندازه دور شکم با فاکتورهای خطر بیماریهای قلبی – عروقی) ۲۲-۲۳ خرداد ۱۳۸۳.

4. The First Regional (EMRO) Congress on Tobacco and Health, Kish Island, CAD morbidity in diabetic and non- diabetic group in smoker, passive smoke and non- smoker.